Nanocalcium-deficient hydroxyapatite–poly (ε-caprolactone)–polyethylene glycol–poly (ε-caprolactone) composite scaffolds

Zhiwei Wang,* Ming Li,* Baoqing Yu, Liehu Cao, Qingsong Yang, Jiacan Su

Department of Orthopedics, Shanghai Hospital, Second Military Medical University, Shanghai, People's Republic of China

*These authors contributed equally to this work

Abstract: A bioactive composite of nano calcium-deficient apatite (n-CDAP) with an atom molar ratio of calcium to phosphate (Ca/P) of 1.50 and poly(ε-caprolactone)–poly(ethylene glycol)–poly(ε-caprolactone) (PCL–PEG–PCL) was synthesized, and a composite scaffold was fabricated. The composite scaffolds with 40 wt% n-CDAP contained well interconnected macropores around 400 µm, and exhibited a porosity of 75%. The weight-loss ratio of the n-CDAP/PCL–PEG–PCL was significantly greater than nano hydroxyapatite (n-HA, Ca/P = 1.67)/PCL–PEG–PCL composite scaffolds during soaking into phosphate-buffered saline (pH 7.4) for 70 days, indicating that n-CDAP-based composite had good degradability compared with n-HA. The viability ratio of MG-63 cells was significantly higher on n-CDAP than n-HA-based composite scaffolds at 3 and 5 days. In addition, the alkaline phosphatase activity of the MG-63 cells cultured on n-CDAP was higher than n-HA-based composite scaffolds at 7 days. Histological evaluation showed that the introduction of n-CDAP into PCL–PEG–PCL enhanced the efficiency of new bone formation when the composite scaffolds were implanted into rabbit bone defects. The results suggested that the n-CDAP-based composite exhibits good biocompatibility, biodegradation, and osteogenesis in vivo.

Keywords: nano calcium-deficient apatite, composite scaffold, degradability, cell responses, osteogenesis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.